$AMS

American Shared Hospital Services (NYSE American: AMS) reported a Q2 2026 net loss of $514,000, or $0.07 per diluted share, widening from a $280,000 loss a year earlier, despite revenue rising 19.2% to $8.43 million. Direct patient services drove growth, while gross profit and operating loss worsened. Cash rose to $6.511 million at June 30, 2026, and the company later arranged financing with Fifth Third Bank.

American Shared Hospital Services (AMS) reported Q2 2026 earnings call highlights including 19% year-over-year revenue growth driven by direct patient services, higher international Gamma Knife volumes, and improving proton beam performance. Proton beam revenue rose 22% to about $2.3M in the quarter and $4.3M for six months. Reported results were impacted by $285k legal costs and a $909k credit-loss allowance. Cash equivalents and restricted cash were about $6.8M.

American Shared Hospital Services’ Q2 2026 call said it is shifting from equipment leasing to a radiation oncology platform focused on direct patient services. Management cited 19% revenue growth tied to higher Rhode Island volumes and improved international results after technology upgrades, including Peru’s Gamma Knife and Orlando proton therapy. It reported $4.4M cash from operations in H1 2026 and is evaluating options for a $15.5M debt obligation under a Fifth Third amendment.

American Shared Hospital Services (NYSE: AMS) reported Q2 2026 revenue of $8.43M and $15.51M for the first half, up from $7.07M and $13.18M a year earlier, driven by direct patient services and higher PBRT and Gamma Knife volumes. The company posted net losses of $0.51M in Q2 and $1.13M for six months and disclosed substantial doubt about its going concern due to covenant breaches and debt default notices.

American Shared Hospital Services reported Q2 2026 sales of $8.43 million versus $7.07 million a year earlier. Net loss was $0.514 million versus $0.28 million. Basic and diluted loss per share were $0.07 versus $0.04. For six months, sales rose to $15.51 million from $13.18 million, with net loss of $1.13 million versus $0.905 million.

American Shared Hospital Services (AMS) reported Q2 2026 revenue up 19% year over year to $8.4M, citing growth in Direct Patient Services and international markets. The company said cash generation was strong, but noted a $909K credit loss and refinancing needs as key risks. It attributed the outlook to strategic investments and operational improvements.

American Shared Hospital Services reported Q2 2026 revenue of $8.4 million, up 19.2% year over year and above the $7.56 million forecast. Adjusted EPS was a loss of $0.07 versus an expected loss of $0.02. Direct patient services rose to $4.9 million and proton beam revenue to about $2.3 million. Cash and equivalents were $6.8 million; management discussed refinancing debt due in 2027.

American Shared Hospital Services (AMEX: AMS) reported Q2 2026 revenue of $8.4 million, up 19% year over year. Direct patient services rose about 40% to $4.9 million, while Proton Beam Radiation Therapy revenue increased 22% to about $2.3 million. Adjusted EBITDA fell to about $1.3 million from $1.7 million. Cash increased to $6.8 million by quarter end.

American Shared Hospital Services (AMEX:AMS) held its Q2 2026 earnings call. The company reported Q2 revenue of about $8.4 million, up 19% year over year, and first-half revenue up 18% to over $15.5 million. It cited higher patient volumes, Proton Beam activity, and international operations. First-half operating cash was $4.4 million and cash rose over 80% to $6.8 million, despite a $909,000 credit-loss charge.

AMERICAN SHARED HOSPITAL SERVICES (AMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1004185.htm EXHIBIT 99.1 ex_1004185.htm Exhibit 99.1 American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results Second Quarter Revenue Increased 19% to $8.4 Million Driven by Strong Growth from Direct Patient Services Operating Cas